XCUR
EXICURE, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.25
−7.41%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.24
From 52W high−82.85%
Volume22613.00
Market cap$8.18M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.24
From 52W high
−82.85%
Volume
22613.00
Market cap
$8.18M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
43.9
MomentumView details →
1D Return
−7.41%
YTD Return
−76.20%
SummaryUpdated Jun 1, 2026
Exicure, Inc. (NASDAQ:XCUR) is a biotechnology company founded in 2011 and headquartered in Chicago, Illinois. The company went public in May 2018 and focuses on developing innovative therapies for neurological disorders and hair loss using its proprietary spherical nucleic acid (SNA) technology platform. Exicure operates as a clinical-stage biopharmaceutical company with strategic partnerships including collaborations with major pharmaceutical companies AbbVie and Ipsen to advance its novel therapeutic candidates.
Similar companies
Latest newsMore news →
Nasdaq granted Exicure, Inc. an extension through December 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(b)(1) regarding stockholders' equity.4d agoExicure announced it will issue 172,058 shares of common stock to GPCR Therapeutics in August 2026 to settle a $1.0 million clinical milestone payment obligation under their License and Collaboration Agreement.48d ago